Selected clinical highlights from the 2010 ERS congress in Barcelona

European Respiratory Journal

Volumn 38, Issue 1, 2011, Pages 209-217

  Cordeiro, C Robalo ^a   Singh, S ^b   Herth, F J F ^c   Ley, S ^c,d   Chavannese, N H ^e   Clini, E ^f   Cottin, V ^g,h  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF TORONTO   (Canada)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^g LOUIS PRADEL HOSPITAL   (France)

^h UNIVERSITÉ LYON 1   (France)

Author keywords

Interstitial lung disease; Interventional pneumology; Lymphangioleiomyomatosis; Pulmonary fibrosis; Pulmonary hypertension; Rehabilitation

Indexed keywords

GAMMA1B INTERFERON; OCTREOTIDE; PIRFENIDONE; PLACEBO;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MAGNETIC RESONANCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONFERENCE PAPER; DRUG DOSE COMPARISON; EARLY DIAGNOSIS; ENDOBRONCHIAL BLOCKING DEVICE; ENDOSCOPIC LUNG VOLUME REDUCTION; ENDOSCOPIC SURGERY; EXERCISE TEST; EXERCISE TOLERANCE; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IMPLANT; INTERSTITIAL PNEUMONIA; LONG TERM CARE; LUNG DIFFUSION CAPACITY; LUNG EMPHYSEMA; LYMPHANGIOLEIOMYOMATOSIS; MINIMALLY INVASIVE PROCEDURE; MUSCLE STRENGTH; NONHUMAN; OXYGEN CONSUMPTION; PHENOTYPE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; PULMONARY REHABILITATION; QUADRICEPS FEMORIS MUSCLE; RESPIRATORY CARE; TELEMEDICINE; TOTAL LUNG CAPACITY; TRANSBRONCHIAL BIOPSY;

AGED; EMPHYSEMA; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES, INTERSTITIAL; LYMPHANGIOLEIOMYOMATOSIS; MALE; MIDDLE AGED; PHENOTYPE; PROGNOSIS; PULMONARY FIBROSIS; PULMONARY MEDICINE; RADIOGRAPHY, THORACIC; SPAIN; TELEMEDICINE;

EID: 79960189512     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00039011     Document Type: Conference Paper

References (64)

1. Herth FJF, Gompelmann D, Ernst A, et al. Endoscopic lung volume reduction. Respiration 2010; 79: 5-13.
2. Tamm M, Ortmann M, Ferke B, et al. Bronchial valve implantation by flexible bronchoscopy in high risk patients with advanced COPD. Eur Respir J 2010; 36: Suppl. 54, 612s.
3. Wood DE, McKenna RJ Jr, Yusen RD, et al. A multicenter trial of an intrabronchial valve for treatment of severe emphysema. J Thoracic Cardiovasc Surg 2007; 133: 65-73.
4. Coxson HO, Nasute Fauerbach PV, Storness-Bliss C, et al. Computed tomography assessment of lung volume changes after bronchial valve treatment. Eur Respir J 2008; 32: 1443-1450.
5. Springmeyer SC, Bolliger CT, Waddell TK, et al. IBV Valve Pilot Trials Research Teams. Treatment of heterogeneous emphysema using the spiration IBV valves. Thorac Surg Clin 2009; 19: 247-253.
6. Sterman DH, Mehta AC, Wood DE, et al. IBV Valve US Pilot Trial Research Team. A multicenter pilot study of a bronchial valve for the treatment of severe emphysema. Respiration 2010; 79: 222-233.
7. Hutsebaut N, Tondeur M, Geltner C, et al. Pulmonary perfusion changes after bronchial valve treatment for predominant upper lobe emphysema. Eur Respir J 2010; 36: Suppl. 54, 612s.
8. Eberhardt R, Gompelmann D, Schuhmann M, et al. Unilateral vs. bilateral endoscopic lung volume reduction in patients with severe heterogeneous emphysema: A comparative randomised case study. Eur Respir J 2010; 36: Suppl. 54, 612s.
9. Herth FJF, Eberhardt R, Ernst A. Pilot study of an improved lung volume reduction coil for the treatment of emphysema. Am J Respir Crit Care Med 2009; 179: A6160.
10. Slebos DJ, Kerstjens HAM, Ernst A, et al. Bronchoscopic lung volume reduction coil treatment of severe heterogeneous emphysema. Eur Respir J 2010; 36: Suppl. 54, 612s-613s.
11. Herth FJF, Stanzel F, Magnussen H, et al. A dose ranging study of the Aeris polymeric lung volume reduction (PLVR) system in patients with advanced upper lobe predominant (ULP) emphysema. Eur Respir J 2009; 35: Suppl. 53, 305s.
12. Herth F, Eberhardt R, Stanzel F, et al. Responses to polymeric lung volume reduction (PLVR) therapy at 6 months in patients with GOLD stage III emphysema. Eur Respir J 2010; 36: Suppl. 54, 612s.
13. Slebos DJ, Shah PL, Cardoso PFG, et al. Exhale airway stents for emphysema (EASE) trial: Proof of initial bronchoscopic lung volume reduction. Eur Respir J 2010; 36: Suppl. 54, 375s-376s.
14. Zagaceta J, Bastarrika G, Saiz R, et al. Impact of emphysema on the clinical presentation of mild to moderate COPD. Eur Respir J 2010; 36: Suppl. 54, 176s-177s.
15. Camiciottoli G, Bigazzi F, Paoletti M, et al. Clinical identification of CT-determined COPD phenotypes. Eur Respir J 2010; 36: Suppl. 54, 45s.
16. Han M, Washko G, Dransfield M, et al. CT phenotype correlates with health status and BODE in COPD. Eur Respir J 2010; 36: Suppl. 54, 1012s.
17. Vestbo J, on behalf of the ECLIPSE steering committee, scientific committee and investigators. Phenotypes and biomarkers: initial 3-year findings from the ECLIPSE study - Introduction. Eur Respir J 2010; 36: Suppl. 54, 1043s.
18. Grydeland TB, Dirksen A, Coxson HO, et al. Quantitative computed tomography measures of emphysema and airway wall thickness are related to respiratory symptoms. Am J Respir Crit Care Med 2010; 181: 353-359.
19. Shah P, Slebos DJ, Cardoso PFG, et al. Late breaking abstract: EXHALE airway stents for emphysema (EASE) trial: CT analysis shows stent-based regional changes mediate early benefit & later loss. Eur Respir J 2010; 36: Suppl. 54, 969s.
20. Park SW, Park JS, Jang AS, et al. Volumetric CT emphysema quantification for predicting pulmonary hypertension in patients with moderate to severe stable COPD. Eur Respir J 2010; 36: Suppl. 54, 234s-235s.
21. Gomberg-Maitland M, Maffessanti F, Patel A, et al. Three dimensional (3D) analysis of septal curvature from cardiac magnetic resonance images to determine pulmonary hypertension severity. Eur Respir J 2010; 36: Suppl. 54, 1023s.
22. Crawley S, Johnson M, Peacock A. Prognostic value of right ventricular mass and function in connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J 2010; 36: Suppl. 54, 200s.
23. van de Veerdonk M, Marcus J, Westerhof N, et al. In pulmonary hypertension changes in right ventricular ejection fraction better predict mortality than changes in pulmonary vascular resistance. Eur Respir J 2010; 36: Suppl. 54, 7s.
24. Fibla J, Molins L, Blanco A, et al. Prospective multicentric study to evaluate the role of video-assisted thoracoscopic lung biopsy in the diagnosis of interstitial lung disease: Evolving concepts. Eur Respir J 2010; 36: Suppl. 54, 129s.
25. Kiral H, Ceylan T, Kupeli M, et al. Does surgical lung biopsy change the diagnosis and treatment in interstitial lung diseases? Eur Respir J 2010; 36: Suppl. 54, 128s-129s.
26. Krenke K, Lange J, Peradzynska J, et al. Interstitial lung diseases in children - Clinical and pathological characteristics. Eur Respir J 2010; 36: Suppl. 54, 119s-120s.
27. Campainha S, Nogueira C, Brito C, et al. Interstitial lung diseases: Data analysis from a Portuguese respiratory reference hospital. Eur Respir J 2010; 36: Suppl. 54, 133s.
28. King TE Jr. Clinical advances in the diagnosis and therapy of the interstitial lung diseases. Am J Respir Crit Care Med 2005; 172: 268-279.
29. Lettieri CJ, Veerappan GR, Parker JM, et al. Discordance between general and pulmonary pathologists in the diagnosis of interstitial lung disease. Respir Med 2005; 99: 1425-1430. (Pubitemid 41508647)
30. Nicholson AG, Addis BJ, Bharucha H, et al. Inter-observer variation between pathologists in diffuse parenchymal lung disease. Thorax 2004; 59: 500-505. (Pubitemid 38797523)
31. Wells AU, Hirani N. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63: 1-58.
32. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002; 165: 277-304.
33. Berbescu EA, Katzenstein AL, Snow JL, et al. Transbronchial biopsy in usual interstitial pneumonia. Chest 2006; 129: 1126-1131.
34. Casoni GL, Gurioli C, Chhajed PN, et al. The value of transbronchial lung biopsy using jumbo forceps via rigid bronchoscope in diffuse lung disease. Monaldi Arch Chest Dis 2008; 69: 59-64.
35. Tcherakian C, Cottin V, Brillet PY, et al. Progression of idiopathic pulmonary fibrosis (IPF): Lessons from asymmetrical disease. Eur Respir J 2010; 36: Suppl. 54, 645s.
36. du Bois R, Albera C, Bradford W, et al. Percent predicted forced vital capacity (FVC) is a reliable, valid, and responsive measure of clinical status in patients with idiopathic pulmonary fibrosis (IPF). Eur Respir J 2010; 36: Suppl. 54, 646s.
37. Chapron J, Dornic Q, Debray MP, et al. Tolerance and efficacy of slow release octreotide in idiopathic pulmonary fibrosis. The FIBROSAND study. Eur Respir J 2010; 36: Suppl. 54, 42s.
38. Costabel U, Albera C, Bradford W, et al. Pirfenidone dose-response in patients with idiopathic pulmonary fibrosis (IPF): A comprehensive analysis of outcomes in CAPACITY 2. Eur Respir J 2010; 36: Suppl. 54, 41s.
39. Albera C, Bradford W, Costabel U, et al. The magnitude of pirfenidone treatment effect in patients with idiopathic pulmonary fibrosis (IPF): A pooled analysis of outcomes in the CAPACITY (CAP) studies. Eur Respir J 2010; 36: Suppl. 54, 41s-42s.
40. Valeyre D, Albera C, Bradford W, et al. The effect of treatment with pirfenidone on death or lung transplantation in patients with idiopathic pulmonary fibrosis (IPF): Analysis of outcomes in the CAPACITY (CAP) trials. Eur Respir J 2010; 36: Suppl. 54, 42s.
41. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171: 1040-1047. (Pubitemid 40616955)
42. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821-829.
43. Azuma A, Taguchi Y, Ogura T, et al. Exploratory analysis of phase III trial of pirfenidone: Most effective population in patients with idiopathic pulmonary fibrosis (IPF). Eur Respir J 2010; 36: Suppl. 54, 41s.
44. Taguchi Y, Ebina M, Hashimoto S, et al. Extended analysis of phase III trial of pirfenidone: More pronounced effect in mild impairment of patients with idiopathic pulmonary fibrosis (IPF). Eur Respir J 2010; 36: Suppl. 54, 42s.
45. Johnson SR, Cordier JF, Lazor R, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J 2010; 35: 14-26.
46. Seyama K, Kumasaka T, Souma S, et al. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol 2006; 4: 143-152. (Pubitemid 46070353)
47. Glasgow CG, Avila NA, Lin JP, et al. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest 2009; 135: 1293-1300.
48. Young LR, Vandyke R, Gulleman PM, et al. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest 2010; 138: 674-681.
49. Kelly J, Coissi G, Kemp S, et al. Comparison of handheld dynamometry with strain gauge for measuring quadriceps strength in COPD patients. Eur Respir J 2010; 36: Suppl. 54, 12s.
50. Zainuldin R, Mackey M, Alison J. Prescribing walking training intensity from the incremental shuttle walk test for people with COPD. Eur Respir J 2010; 36: Suppl. 54, 3s.
51. Vaes AW, Wouters EFM, Franssen FME, et al. Task-related oxygen uptake (VO2) during domestic activities of daily life (ADLs) in COPD patients and healthy subjects. Eur Respir J 2010; 36: Suppl. 54, 2s-3s.
52. McNamara RJ, Alison JA, McKenzie DK, et al. Water-based exercise in people with COPD and physical co-morbid conditions: A randomized controlled trial. Eur Respir J 2010; 36: Suppl. 54, 3s.
53. Barne M, Singh M, Gaikwad K, et al. Reasons for underutilization of spirometry by practicing physicians in India. Eur Respir J 2010; 36: Suppl. 54, 768s.
54. Minas M, Konstantikaki V, Batavanis G, et al. Comparison of a network of primary care physicians and an open spirometry programme for the early diagnosis of COPD. Eur Respir J 2010; 36: Suppl. 54, 369s.
55. Thorn J, Tilling B, Lisspers K, et al. Late Breaking Abstract: Improved prediction of COPD in patients at risk by lung function pre-screening in primary care. Eur Respir J 2010; 36: Suppl. 54, 137s.
56. Jensen MS, Soerensen TB, Grann O, et al. Structured follow-up of COPD patients according to guidelines in primary care - Using a web-based data capture tool. Eur Respir J 2010; 36: Suppl. 54, 764s.
57. Rikkers-Mutsaerts ERVM, Winters AE, Bakker MJ, et al. Internet-based self-management compared with usual care in adolescents with asthma: A randomised controlled trial. Eur Respir J 2010; 36: Suppl. 54, 984s.
58. Ryan D, Pinnock H, Amanda L, et al. Can mobile phone technology improve asthma control? A randomised trial. Eur Respir J 2010; 36: Suppl. 54, 368s.
59. McLean S, Chandler D, Liu J, et al. Telehealthcare interventions for asthma: Cochrane systematic review and meta-analysis. Eur Respir J 2010; 36: Suppl. 54, 368s.
60. Kruis AL, van Adrichem J, Erkelens MR, et al. Sustained effects of integrated COPD management on health status and exercise capacity in primary care patients. Int J Chron Obstruct Pulmon Dis 2010; 5: 407-413.
61. Menéndez AA, Olmos LG, Navarro GM, et al. Clinical profile of chronic obstructive pulmonary diseases in primary health care. Eur Respir J 2010; 36: Suppl. 54, 999s-1000s.
62. Brusselle G, Jones PW, Perez T, et al. Relationship between comorbidities and patient-reported health status in the European Health-related Quality of Life in COPD study. Eur Respir J 2010; 36: Suppl. 54, 997s.
63. Puhan M, Siebeling L, ter Riet G Characteristics of COPD patients from primary care enrolled in a prospective multicenter cohort study, Eur Respir J 2010; 36: Suppl. 54, 439s.
64. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-1138.